Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy

StatusFinished
Effective start/end date1/12/1430/11/17

Funding

  • Cancer Prevention & Res Inst of TX: $741,414.00

Keywords

  • Biotechnology & Drug Development, Cancer Research, Nanotechnology, Womens Health